Pub Date : 2021-02-01DOI: 10.1097/FAD.0000000000000053
P. Routledge, R. Bracchi, F. Woods
{"title":"Drug interactions with herbal medicines: mechanisms and implications","authors":"P. Routledge, R. Bracchi, F. Woods","doi":"10.1097/FAD.0000000000000053","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000053","url":null,"abstract":"","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"326 1","pages":"1263-1266"},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61684706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-01DOI: 10.1097/00012995-199708000-00002
{"title":"SUBJECT AND DRUG INDEXES TO ADVERSE DRUG REACTION BULLETIN: Nos 320–325 February 2020 – December 2020","authors":"","doi":"10.1097/00012995-199708000-00002","DOIUrl":"https://doi.org/10.1097/00012995-199708000-00002","url":null,"abstract":"","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00012995-199708000-00002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47499216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-01DOI: 10.1097/FAD.0000000000000052
Debdipta Bose, N. Gogtay
Bisphosphonates (BPs) have been in the market for the past 40 years and proven beneficial especially for patients with osteoporosis and prevention of hypercalcemic in malignancy. However, their long-term use raises safety concerns like Atypical femoral fracture and Osteonecrosis of the Jaw whose pathophysiology still remains unclear. Atypical femoral fracture is more commonly seen among BP users with at least six years of therapy and concomitant use of drugs such as glucocorticoids. The most common treatment for atypical femoral fracture is to withdraw the therapy with monitoring of bone resorption markers but the definitive treatment is intramedullary nail fixation where necessary. Hence, physicians must be vigilant to rarer and long-term BP-reported adverse effects and understand the evidence around the use of these drugs including drug free holidays. A structured benefit-risk assessment should be made for every individual patient including communicating the risk of these rare side effects.
{"title":"Bisphosphonate use and the risk of atypical fractures","authors":"Debdipta Bose, N. Gogtay","doi":"10.1097/FAD.0000000000000052","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000052","url":null,"abstract":"Bisphosphonates (BPs) have been in the market for the past 40 years and proven beneficial especially for patients with osteoporosis and prevention of hypercalcemic in malignancy. However, their long-term use raises safety concerns like Atypical femoral fracture and Osteonecrosis of the Jaw whose pathophysiology still remains unclear. Atypical femoral fracture is more commonly seen among BP users with at least six years of therapy and concomitant use of drugs such as glucocorticoids. The most common treatment for atypical femoral fracture is to withdraw the therapy with monitoring of bone resorption markers but the definitive treatment is intramedullary nail fixation where necessary. Hence, physicians must be vigilant to rarer and long-term BP-reported adverse effects and understand the evidence around the use of these drugs including drug free holidays. A structured benefit-risk assessment should be made for every individual patient including communicating the risk of these rare side effects.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47970050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-01DOI: 10.1097/FAD.0000000000000050
H. Horwitz, D. Gotfredsen, T. Christoffersen
Henrik Horwitz, Ditte Resendal a Gotfredsen & Thea Christoffersen Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark Correspondence to Henrik Horwitz, MD, PhD, associate professor, Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark. Tel.: +4529464288. E-mail: henrik_horwitz@hotmail.com and henrik.horwitz@regionh.dk
Henrik Horwitz，Ditte Resendal a Gotfredsen&Thea Christoffersen Bispebjerg and Frederiksberg医院临床药理学系和丹麦哥本哈根大学临床医学系Henrik Horwitz博士、副教授，2400丹麦哥本哈根。电话：+4529464288。电子邮件：henrik_horwitz@hotmail.com和henrik.horwitz@regionh.dk
{"title":"Adverse drug reactions: five historical scandals","authors":"H. Horwitz, D. Gotfredsen, T. Christoffersen","doi":"10.1097/FAD.0000000000000050","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000050","url":null,"abstract":"Henrik Horwitz, Ditte Resendal a Gotfredsen & Thea Christoffersen Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark Correspondence to Henrik Horwitz, MD, PhD, associate professor, Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark. Tel.: +4529464288. E-mail: henrik_horwitz@hotmail.com and henrik.horwitz@regionh.dk","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000050","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48574625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-01DOI: 10.1097/FAD.0000000000000049
J. Andersen, T. Futtrup
Jon T. Andersen & Tina Bergmann Futtrup Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, in concentration between the drug level in plasma and that in breast milk. The higher the concentration of free drug molecules in plasma, the higher the concentration in the breast milk. In the first days after birth the August 2020 No. 323 Founded in 1966 by Professor D M Davies, FRCP, FRCP Ed ISSN 0044–6394
哥本哈根大学比斯堡医院临床药理学部Jon T. Andersen和Tina Bergmann Futtrup，血浆和母乳中药物浓度之间的关系。血浆中游离药物分子的浓度越高，母乳中的浓度就越高。在出生后的第一天，2020年8月第323号由dr . M . Davies教授创立于1966年，FRCP, FRCP Ed ISSN 0044-6394
{"title":"Drugs during lactation","authors":"J. Andersen, T. Futtrup","doi":"10.1097/FAD.0000000000000049","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000049","url":null,"abstract":"Jon T. Andersen & Tina Bergmann Futtrup Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, in concentration between the drug level in plasma and that in breast milk. The higher the concentration of free drug molecules in plasma, the higher the concentration in the breast milk. In the first days after birth the August 2020 No. 323 Founded in 1966 by Professor D M Davies, FRCP, FRCP Ed ISSN 0044–6394","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000049","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41447781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-01DOI: 10.1097/FAD.0000000000000048
M. Pucci, Penelope Roussak, D. Pang, M. Darrad
{"title":"Drug-induced priapism","authors":"M. Pucci, Penelope Roussak, D. Pang, M. Darrad","doi":"10.1097/FAD.0000000000000048","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000048","url":null,"abstract":"","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000048","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43736796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.1097/fad.0000000000000047
J. Andersen, T. Futtrup
{"title":"Drugs in pregnancy","authors":"J. Andersen, T. Futtrup","doi":"10.1097/fad.0000000000000047","DOIUrl":"https://doi.org/10.1097/fad.0000000000000047","url":null,"abstract":"","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/fad.0000000000000047","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42607827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-01DOI: 10.1097/fad.0000000000000046
{"title":"SUBJECT AND DRUG INDEXES TO ADVERSE DRUG REACTION BULLETIN: Nos 314-319 February 2019 - December 2019","authors":"","doi":"10.1097/fad.0000000000000046","DOIUrl":"https://doi.org/10.1097/fad.0000000000000046","url":null,"abstract":"","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/fad.0000000000000046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46314489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-01DOI: 10.1097/FAD.0000000000000045
P. Esbech, J. Schmidt, L. K. Andersen, P. Damkier
Introduction: Drug-induced vasculitis is a rare adverse drug reaction and the potential to induce such a reaction is often established postmarketing. Leukocytoclastic vasculitis a subtype of drug-induced vasculitis often presents itself with palpable purpuric lesions, and often within weeks of initial administration. Case-description: We present a 62-year-old male who presented with leukocytoclastic vasculitis within the first 8 days of apixaban-initiation. Symptoms improved upon discontinuation and resolved after several months of prednisone therapy. Literature review: We conducted a search on PubMed, which yielded 10 reports of leukocytoclastic vasculitis induced by NOACs, of these 10 only 1 had been caused by apixaban, 4 caused by dabigatran and 5 had been caused by rivaroxaban. Of these cases, one presented with leukocytoclastic vasculitis induced by both rivaroxaban and dabigatran, and one case presented successful switch from apixaban to rivaroxaban. Conclusion: Apixaban-induced leukocytoclastic vasculitis is a rare but serious and important adverse reaction.
{"title":"Apixaban-induced leukocytoclastic vasculitis","authors":"P. Esbech, J. Schmidt, L. K. Andersen, P. Damkier","doi":"10.1097/FAD.0000000000000045","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000045","url":null,"abstract":"Introduction: Drug-induced vasculitis is a rare adverse drug reaction and the potential to induce such a reaction is often established postmarketing. Leukocytoclastic vasculitis a subtype of drug-induced vasculitis often presents itself with palpable purpuric lesions, and often within weeks of initial administration. Case-description: We present a 62-year-old male who presented with leukocytoclastic vasculitis within the first 8 days of apixaban-initiation. Symptoms improved upon discontinuation and resolved after several months of prednisone therapy. Literature review: We conducted a search on PubMed, which yielded 10 reports of leukocytoclastic vasculitis induced by NOACs, of these 10 only 1 had been caused by apixaban, 4 caused by dabigatran and 5 had been caused by rivaroxaban. Of these cases, one presented with leukocytoclastic vasculitis induced by both rivaroxaban and dabigatran, and one case presented successful switch from apixaban to rivaroxaban. Conclusion: Apixaban-induced leukocytoclastic vasculitis is a rare but serious and important adverse reaction.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000045","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41379989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-01DOI: 10.1097/FAD.0000000000000044
Tiago Soares, H. Fok
Cytokine release syndrome (CRS) is an adverse drug reaction that is poorly understood but is likely to be increasingly common as more immunotherapeutics are being developed and licensed, principally in the treatment of cancer. Early recognition and aggressive treatment of this potentially rapidly fatal systemic inflammatory response syndrome (SIRS) is the key to a better outcome for this adverse drug reaction.
{"title":"Cytokine release syndrome: a primer for generalists","authors":"Tiago Soares, H. Fok","doi":"10.1097/FAD.0000000000000044","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000044","url":null,"abstract":"Cytokine release syndrome (CRS) is an adverse drug reaction that is poorly understood but is likely to be increasingly common as more immunotherapeutics are being developed and licensed, principally in the treatment of cancer. Early recognition and aggressive treatment of this potentially rapidly fatal systemic inflammatory response syndrome (SIRS) is the key to a better outcome for this adverse drug reaction.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000044","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42272771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：